Trade-Ideas: Abiomed (ABMD) Is Today's Post-Market Leader Stock - TheStreet

Trade-Ideas LLC identified

Abiomed

(

ABMD

) as a post-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Abiomed as such a stock due to the following factors:

  • ABMD has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $69.2 million.
  • ABMD is up 2.5% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ABMD with the Ticky from Trade-Ideas. See the FREE profile for ABMD NOW at Trade-Ideas

More details on ABMD:

ABIOMED, Inc. researches, develops, and sells medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. ABMD has a PE ratio of 31. Currently there are 4 analysts that rate Abiomed a buy, no analysts rate it a sell, and 4 rate it a hold.

The average volume for Abiomed has been 824,500 shares per day over the past 30 days. Abiomed has a market cap of $3.9 billion and is part of the health care sector and health services industry. The stock has a beta of 0.32 and a short float of 6.7% with 3.24 days to cover. Shares are up 147.3% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Abiomed as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

Highlights from the ratings report include:

  • ABMD's very impressive revenue growth exceeded the industry average of 35.9%. Since the same quarter one year prior, revenues leaped by 50.4%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • ABMD has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 5.22, which clearly demonstrates the ability to cover short-term cash needs.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, ABIOMED INC's return on equity significantly exceeds that of both the industry average and the S&P 500.
  • The gross profit margin for ABIOMED INC is currently very high, coming in at 86.10%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 12.06% is above that of the industry average.
  • Net operating cash flow has significantly increased by 242.13% to $10.91 million when compared to the same quarter last year. In addition, ABIOMED INC has also vastly surpassed the industry average cash flow growth rate of -31.77%.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.